Wolters Kluwer Health
may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
your express consent. For more information, please refer to our Privacy Policy.

Long-term durability and incidence of potential mechanical device failure (MDF) are largely unknown. In this study, we investigated the incidence and potential predictors of MDF in continuous flow left ventricular assist device (CF-LVAD) patients. We conducted a retrospective study of all CF-LVADs (type HeartMate II) implanted in our center. MDF was defined as a failure of driveline, inflow–outflow graft, electrical power, drive unit, or motor failure, excluding device failure because of a biologic complication (e.g., device thrombosis, hemolysis, or infections). A total of 69 CF-LVADs were implanted in 59 patients (median support time 344 days [interquartile range {IQR}, 149–712 days], mean age 50.1 ± 10.7 years, 75% male). MDF occurred in 9 (13%) CF-LVAD patients at a median follow-up time of 846 (IQR, 708–1337) days after implantation. Freedom of MDF through the first, second, and third year after LVAD implantation was 100%, 85%, and 64%, respectively. Patients who experienced MDF were significantly longer supported by their LVAD (median 846 [IQR, 708–1337] vs 268 [IQR, 103–481] days; p = 0.001) and were more frequently readmitted because of LVAD-related technical problems (p = 0.002), including a higher rate of LVAD controllers exchange (44% vs 12%, respectively; p = 0.03). The main reason for MDF was a damaged or fractured driveline (n=8, 89%). In 2 patients, sudden death was related to MDF. Patients needing extended CF-LVAD support are at increasing risk for MDF. Various technical problems precede the onset of MDF. Periodical extensive assessment of the technical integrity of the device is urgently needed during long-term LVAD support.

From the Thoraxcenter, *Department of Cardiology, Unit Heart Failure, Transplantation and Mechanical Circulatory, †Department of Intensive Care, and ‡Department of Cardiothoracic Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Submitted for consideration May 2017 ; accepted for publication in revised form August 2017.